Record-Breaking Price Movement
On 04 May 2026, Fredun Pharmaceuticals Ltd surged to an intraday high of Rs. 2,424, representing an 8.66% increase during the trading session. The stock closed with a day gain of 5.56%, substantially outperforming the Sensex, which rose by only 0.90% on the same day. This price marks a new 52-week and all-time high for the company, underscoring its robust momentum in the Pharmaceuticals & Biotechnology sector.
The stock has been on a positive trajectory, gaining for two consecutive days and delivering an 11.33% return over this short period. It has also outperformed its sector by 3.59% on the day of this milestone. Fredun Pharmaceuticals is trading comfortably above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a strong bullish trend.
Long-Term Market Outperformance
Fredun Pharmaceuticals Ltd’s price appreciation over various time horizons highlights its exceptional market performance. Over the past year, the stock has delivered a staggering return of 235.71%, vastly outperforming the Sensex’s decline of 3.59% during the same period. Year-to-date, the stock has gained 49.21%, while the Sensex has fallen by 8.93%.
Looking further back, the company has generated a 3-year return of 138.84% compared to the Sensex’s 25.68%, and a 5-year return of 473.90% versus the Sensex’s 60.84%. Over a decade, Fredun Pharmaceuticals has achieved an extraordinary 16,175.05% return, dwarfing the Sensex’s 209.18% gain. These figures reflect the company’s sustained ability to create shareholder value over the long term.
Financial Strength and Growth Metrics
Fredun Pharmaceuticals’ strong market performance is supported by solid financial fundamentals. The company has demonstrated healthy long-term growth with net sales increasing at a compound annual growth rate (CAGR) of 38.09% over five years. Operating profit has grown even more impressively at 58.31% annually.
In the most recent quarter, the company reported net sales of Rs. 160.93 crores, reflecting a 56.70% increase. Operating profit before depreciation and interest (PBDIT) reached a record Rs. 26.34 crores, while profit before tax excluding other income (PBT less OI) hit Rs. 14.00 crores, the highest recorded to date. The operating profit margin for the quarter stood at 16.37%, indicating efficient cost management alongside revenue growth.
Return on capital employed (ROCE) is reported at 20.2%, suggesting a fair valuation relative to the company’s capital base. The enterprise value to capital employed ratio is 4.4, which aligns with the company’s valuation compared to its peers’ historical averages.
Valuation and Market Metrics
As of 04 May 2026, Fredun Pharmaceuticals trades at a price-to-earnings (P/E) ratio of 38x, with a price-to-book value (P/BV) of 7.84x. The enterprise value to EBITDA stands at 16.81x, and EV to EBIT at 18.12x. The PEG ratio is notably low at 0.67x, reflecting the company’s strong earnings growth relative to its valuation.
Dividend yield remains modest at 0.03%, with the latest dividend declared at Rs. 0.7 per share and a payout ratio of 2.11%. The ex-dividend date was 23 September 2025.
Promoter Confidence and Shareholding
Promoter stake in Fredun Pharmaceuticals has increased by 1.11% over the previous quarter, now standing at 44.17%. This rise in promoter holding signals a strong vote of confidence in the company’s business prospects and governance. Notably, there is no promoter share pledging, which adds to the stability of the shareholding structure.
Technical Analysis and Market Sentiment
The overall technical trend for Fredun Pharmaceuticals is bullish, with the trend having shifted to this status on 09 April 2026 at a price level of Rs. 1,830. Key technical indicators such as MACD, Bollinger Bands, KST, and Dow Theory all signal bullish momentum on both weekly and monthly timeframes. The stock’s immediate support level is at Rs. 666, the 52-week low, while the major resistance levels have been surpassed as the stock reached its new high.
Delivery volumes have also shown strength, with a 1-day delivery volume increase of 49.72% compared to the 5-day average, and a 1-month delivery volume change of 11.89%, indicating sustained investor participation in the stock.
Quality Assessment and Financial Health
Fredun Pharmaceuticals is classified as an average quality company based on long-term financial performance. While growth metrics are excellent, with a 5-year sales growth of 38.09% and EBIT growth of 58.31%, the company’s capital structure and leverage ratios indicate moderate debt levels. The average debt to EBITDA ratio is 2.89, and net debt to equity stands at 1.03, reflecting a leveraged position.
Management risk is assessed as average, with no promoter pledging and low institutional holdings at 3.89%. Return on equity (ROE) and ROCE are relatively weak at 13.09% and 14.74% respectively, but the company’s strong growth trajectory compensates for these metrics.
Summary of Recent Financial Trends
The company’s short-term financial trend remains positive, with the December 2025 quarter showing very positive results. Quarterly net sales grew by 56.70% to Rs. 160.93 crores, while profit before tax excluding other income reached Rs. 14.00 crores. Operating profit margins improved, and earnings per share (EPS) for the quarter hit Rs. 22.20, the highest recorded.
Interest expenses were noted as the highest at Rs. 10.55 crores, which is a factor to monitor, but overall profitability and operational efficiency remain strong.
Conclusion
Fredun Pharmaceuticals Ltd’s achievement of an all-time high price of Rs. 2,424 on 04 May 2026 reflects a culmination of sustained growth, strong financial performance, and positive market sentiment. The company’s impressive returns over multiple time frames, combined with solid quarterly results and increasing promoter confidence, underscore its significant position within the Pharmaceuticals & Biotechnology sector. Trading above all key moving averages and supported by bullish technical indicators, Fredun Pharmaceuticals continues to demonstrate resilience and strength in its market journey.
